JP2018526987A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526987A5 JP2018526987A5 JP2018504942A JP2018504942A JP2018526987A5 JP 2018526987 A5 JP2018526987 A5 JP 2018526987A5 JP 2018504942 A JP2018504942 A JP 2018504942A JP 2018504942 A JP2018504942 A JP 2018504942A JP 2018526987 A5 JP2018526987 A5 JP 2018526987A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- polypeptide
- acid residue
- acid residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510446747 | 2015-07-27 | ||
| CN201510446747.4 | 2015-07-27 | ||
| PCT/CN2016/090800 WO2017016430A1 (zh) | 2015-07-27 | 2016-07-21 | 一种肿瘤抑制肽 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526987A JP2018526987A (ja) | 2018-09-20 |
| JP2018526987A5 true JP2018526987A5 (enExample) | 2019-08-08 |
| JP6903633B2 JP6903633B2 (ja) | 2021-07-14 |
Family
ID=57883958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018504942A Active JP6903633B2 (ja) | 2015-07-27 | 2016-07-21 | 腫瘍抑制ペプチド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10351613B2 (enExample) |
| EP (1) | EP3330285B1 (enExample) |
| JP (1) | JP6903633B2 (enExample) |
| CN (17) | CN113912705B (enExample) |
| WO (1) | WO2017016430A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113912705B (zh) * | 2015-07-27 | 2023-12-22 | 上海贺普药业股份有限公司 | 一种肿瘤抑制肽 |
| CN113244370A (zh) * | 2020-02-13 | 2021-08-13 | 珠海市藤栢医药有限公司 | 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途 |
| CN115991739B (zh) * | 2021-12-20 | 2023-10-20 | 珠海市藤栢医药有限公司 | 一种抗肿瘤的多肽及其制备方法和应用 |
| CN117801060A (zh) * | 2022-09-26 | 2024-04-02 | 深圳碳云智肽药物科技有限公司 | 一种抗肿瘤多肽及应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3840262B2 (ja) * | 1995-10-23 | 2006-11-01 | ザ チルドレンズ メディカル センター コーポレイション | 治療用の抗血管新生組成物および方法 |
| US5854205A (en) * | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
| US6174861B1 (en) * | 1996-10-22 | 2001-01-16 | The Children's Medical Center Corporation | Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein |
| US6825167B1 (en) * | 2000-04-03 | 2004-11-30 | Regents Of The University Of Minnesota | Genetic modification of endostatin |
| CN1239516C (zh) * | 2002-02-08 | 2006-02-01 | 中国医学科学院基础医学研究所 | 肿瘤坏死因子相关细胞凋亡诱导配体胞外区突变多肽及其制法与用途 |
| BR0308090A (pt) * | 2002-03-01 | 2006-04-11 | Univ Tulane | conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos |
| US20040091465A1 (en) * | 2002-06-26 | 2004-05-13 | Zachary Yim | Therapeutic antiangiogenic compositions and methods |
| US7078485B2 (en) * | 2002-12-05 | 2006-07-18 | Yantai Medgenn Ltd. | N-terminal modified recombinant human endostatin and its production |
| US7524811B2 (en) * | 2003-08-29 | 2009-04-28 | Children's Medical Center Corporation | Anti-angiogenic peptides from the N-terminus of endostatin |
| CN1875104A (zh) * | 2003-08-29 | 2006-12-06 | 儿童医学中心公司 | 来自内皮抑素n－末端的抗血管生成肽 |
| EP1687426B1 (en) * | 2003-08-29 | 2008-07-16 | Children's Medical Center Corporation | Antiangiogenicpeptides for treating or preventing endometriosis |
| ES2325344B1 (es) * | 2004-11-02 | 2010-06-09 | Univ Madrid Autonoma | Inhibidores de angiogenesis multifuncionales y multivalentes. |
| CN100586961C (zh) * | 2006-05-16 | 2010-02-03 | 中国人民解放军军事医学科学院野战输血研究所 | 对肿瘤细胞具有抑制作用的融合蛋白及其编码基因与应用 |
| CN101062954A (zh) * | 2006-05-16 | 2007-10-31 | 中国人民解放军军事医学科学院野战输血研究所 | 具有抗血管生成作用的融合蛋白及其编码基因与应用 |
| CA2683463A1 (en) * | 2007-04-11 | 2008-10-23 | Gene Signal International Sa | Anti-tumor variants and fragments of protein 497c, and uses thereof |
| CN101096671A (zh) * | 2007-06-01 | 2008-01-02 | 徐寒梅 | 血管生成抑制剂hm-x及其制备方法和应用 |
| EP2173377B1 (en) * | 2007-06-26 | 2017-11-29 | University of Miami | Antibody-endostatin fusion protein and its variants |
| CN102924578A (zh) * | 2011-08-09 | 2013-02-13 | 哈药集团技术中心 | 抗肿瘤多肽及其制备方法和抗肿瘤应用 |
| EP2561888A1 (en) * | 2011-08-23 | 2013-02-27 | Deutsches Krebsforschungszentrum | Protein comprising NC-1 for treating angiogenesis-related diseases |
| CN113912705B (zh) * | 2015-07-27 | 2023-12-22 | 上海贺普药业股份有限公司 | 一种肿瘤抑制肽 |
-
2016
- 2016-07-21 CN CN202111152378.XA patent/CN113912705B/zh active Active
- 2016-07-21 WO PCT/CN2016/090800 patent/WO2017016430A1/zh not_active Ceased
- 2016-07-21 CN CN202111153273.6A patent/CN115433268B/zh active Active
- 2016-07-21 US US15/746,978 patent/US10351613B2/en active Active
- 2016-07-21 CN CN201680044076.1A patent/CN107922475B/zh active Active
- 2016-07-21 CN CN202111153309.0A patent/CN115433269B/zh active Active
- 2016-07-21 CN CN202111155210.4A patent/CN113943364B/zh active Active
- 2016-07-21 CN CN202111153255.8A patent/CN115433267B/zh active Active
- 2016-07-21 EP EP16829796.8A patent/EP3330285B1/en active Active
- 2016-07-21 CN CN202111152268.3A patent/CN113717277B/zh active Active
- 2016-07-21 CN CN202111152259.4A patent/CN113717276B/zh active Active
- 2016-07-21 CN CN202111151032.8A patent/CN113717274B/zh active Active
- 2016-07-21 CN CN202111155546.0A patent/CN113980120B/zh active Active
- 2016-07-21 CN CN202111152258.XA patent/CN113717275B/zh active Active
- 2016-07-21 CN CN202111155175.6A patent/CN113943363B/zh active Active
- 2016-07-21 CN CN202111155543.7A patent/CN113980119B/zh active Active
- 2016-07-21 CN CN202111155244.3A patent/CN114031683B/zh active Active
- 2016-07-21 CN CN202111155262.1A patent/CN113943365B/zh active Active
- 2016-07-21 JP JP2018504942A patent/JP6903633B2/ja active Active
- 2016-07-21 CN CN202111153334.9A patent/CN115433270B/zh active Active
- 2016-07-21 CN CN202111152272.XA patent/CN113717278B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| JP2018509935A5 (enExample) | ||
| JP2022514255A5 (enExample) | ||
| JP2017006120A5 (enExample) | ||
| JP2019525753A5 (enExample) | ||
| JP2015519313A5 (enExample) | ||
| EA202191651A1 (ru) | Бициклические пептидные лиганды, специфичные к mt1-mmp | |
| JP2018508489A5 (enExample) | ||
| JP2022513223A5 (enExample) | ||
| JP2011511753A5 (enExample) | ||
| JP2022512478A5 (enExample) | ||
| JP2019533722A5 (enExample) | ||
| JP2018510215A5 (enExample) | ||
| JP2018509936A5 (enExample) | ||
| JP2017528117A5 (enExample) | ||
| JP2016501829A5 (enExample) | ||
| JP2016521257A5 (enExample) | ||
| IL308807B2 (en) | Combination therapy for treating cancer | |
| IN2014KN01713A (enExample) | ||
| IN2014KN01716A (enExample) | ||
| JP2017502081A5 (enExample) | ||
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| JP2015520178A5 (enExample) | ||
| JP2018500385A5 (enExample) | ||
| JP2019534884A5 (enExample) |